Pharmaceutical

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC

The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.

Jun 25, 2025 - 06:00
FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC
The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.
Read the original article

Tags:

Previous Article

FDA genAI reviews hinge on clarity of dossiers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors

STAT+: In response to criticism, FDA publishes new data...

Dec 15, 2023

STAT+: Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries

STAT+: Vertex faces renewed calls to widen access to it...

Aug 3, 2023

Randomized controlled trials are the ‘gold standard’ of research — but a difficult fit for trans care

Randomized controlled trials are the ‘gold standard’ of...

Sep 16, 2023